Key result
Statin treatment significantly reduced epicardial adipose tissue attenuation by 6% over 1 year, with no significant difference between 80 mg atorvastatin and 40 mg pravastatin (p=0.55).
Why the study?
Statins reduce epicardial adipose tissue volume, but whether they affect epicardial adipose tissue attenuation was unknown.
Does atorvastatin 80 mg daily reduce epicardial adipose tissue attenuation more than pravastatin 40 mg daily in postmenopausal women with dyslipidemia and subclinical atherosclerosis?
RCT (n=420)
Double-blind
Double-blind approach to either atorvastatin, 80 mg/d, and matching pravastatin placebo or pravastatin, 40 mg/d, and matching atorvastatin placebo
Yes
Does atorvastatin 80 mg daily reduce epicardial adipose tissue attenuation more than pravastatin 40 mg daily in postmenopausal women with dyslipidemia and subclinical atherosclerosis?
Statins reduce epicardial adipose tissue attenuation independent of lipid lowering, suggesting a potential anti-inflammatory or metabolic pleiotropic effect.
Statin therapy reduces EAT attenuation equally across regimens; confirms pleiotropic effects independent of lipid lowering in postmenopausal women.
Background High epicardial adipose tissue (EAT) attenuation (Hounsfield units [ HUs] ) on computed tomography is considered a marker of inflammation and is associated with an increased risk of cardiovascular events. Statins reduce the volume of EAT , but it is unknown whether they affect EAT HUs . Methods and Results We reviewed the chest computed tomographic scans of 420 postmenopausal women randomized to either 80 mg of atorvastatin or 40 mg of pravastatin daily and rescanned after 1 year to measure change in coronary artery calcium score. EAT HUs were measured near the proximal right coronary artery and remote from any area of coronary artery calcium. Computed tomographic images were also queried for subcutaneous adipose tissue (SubQ) attenuation ( HUs ) change over time. The mean patients' age was 65±6 years. The baseline EAT HU value was higher than the SubQ HU value (-89.4±24.0 HU versus -123.3±30.4 HU ; P<0.001). The EAT HU value decreased significantly in the entire cohort (-5.4±29.7 HU [-6% change]; P<0.001), but equally in the patients given atorvastatin and pravastatin (-6.35+31 HU and -4.55+28 HU ; P=0.55). EAT HU change was not associated with change in total cholesterol, low-density lipoprotein cholesterol, coronary artery calcium, and EAT volume (all P=not significant). Change in high-density lipoprotein cholesterol was marginally associated with EAT HU change ( P=0.07). Statin treatment did not induce a change in SubQ HUs . Conclusions Statins induced a decrease in EAT HUs over time, independent of intensity of low-density lipoprotein cholesterol lowering. The positive effect on EAT and the neutral effect on SubQ suggest that statins induced a decrease in metabolic activity in EAT by reduction in cellularity, vascularity, or inflammation. The clinical significance of the observed change in EAT HUs remains to be demonstrated.
No takes yet. Share an insight, caveat, or question.
Raggi et al. (2019) conducted an RCT in Dyslipidemia and subclinical coronary atherosclerosis (n=420). Atorvastatin vs. Pravastatin 40 mg daily was evaluated on Change in epicardial adipose tissue (EAT) attenuation (HUs) (p=0.55). Statin treatment significantly reduced epicardial adipose tissue attenuation by 6% over 1 year, with no significant difference between 80 mg atorvastatin and 40 mg pravastatin (p=0.55).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: